JW2286

JW2286 (also known as ST-2286) is a first-in-class, orally administered small molecule inhibitor that selectively targets the STAT3 (signal transducer and activator of transcription 3) protein. STAT3 is a transcription factor implicated in cancer cell growth, proliferation, metastasis, and drug resistance. Abnormal activation of STAT3 is associated with various solid tumors—including triple-negative breast cancer, gastric cancer, and colorectal cancer—as well as inflammatory and autoimmune diseases. JW2286 acts as an allosteric inhibitor by directly binding to the N-terminal domain of STAT3. This dual mechanism blocks both STAT3-mediated gene transcription and mitochondrial function in tumor cells, leading to apoptosis and inhibition of tumor progression. Preclinical studies have demonstrated superior efficacy and safety compared to other clinical competitors targeting similar pathways. The drug is being developed by JW Pharmaceutical for use in solid tumors with high unmet medical needs[1][2][3][4][5][8].